AZN•benzinga•
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
Summary
FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 31, 2025 by benzinga